WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Martin J. Waters
Partner
Corporate
San Diego
mwaters@wsgr.com

D858-350-2308

Download vCard
LinkedIn
Open PDF
  • A Proven Company Builder

    With more than 30 years of experience providing corporate and securities counsel, Marty has been instrumental in starting, building, and shepherding numerous emerging growth companies through IPOs or strategic partnerships.

  • Southern California Focus

    A founding partner of the San Diego office and Southern California corporate practice, Marty leads the firm's efforts in representing public and private growth companies in San Diego, Orange County, and Los Angeles.

  • A Recognized Practitioner

    Ranked Band 1 by Chambers USA for his corporate work in Southern California, Marty has been recognized as a leading corporate attorney in multiple editions of Chambers USA, as well as San Diego Metropolitan Magazine, IPO Journal, and LMG Life Sciences.

Martin (Marty) Waters is a corporate and securities partner in the San Diego office. He is a founding partner of the firm's San Diego office and Southern California corporate practice. He was a partner in the Palo Alto office until opening the San Diego office in 2004. He is a current member of the firm's board of directors.

Marty is a proven company builder with more than 30 years of experience providing corporate and securities counsel to high growth private and public companies. He has been instrumental in starting, building, and shepherding numerous emerging growth life sciences and technology companies through IPOs or strategic partnerships. Marty also represents several public companies in a general counsel capacity, as well as investment banks and placement agents in PIPEs and public offerings. Marty has counseled issuers and underwriters in more than 50 offerings.

Recognized in Chambers USA: America's Leading Lawyers for Business since 2011, Marty is “highly respected for the superlative quality of the corporate counsel he offers corporate clients.” Sources describe him as a “a trusted partner” who “consistently delivers great advice” with a “specialty in managing complex and difficult stalemates.”

Experience

Martin (Marty) Waters is a corporate and securities partner in the San Diego office. He is a founding partner of the firm's San Diego office and Southern California corporate practice. He was a partner in the Palo Alto office until opening the San Diego office in 2004. He is a current member of the firm's board of directors.

Marty is a proven company builder with more than 30 years of experience providing corporate and securities counsel to high growth private and public companies. He has been instrumental in starting, building, and shepherding numerous emerging growth life sciences and technology companies through IPOs or strategic partnerships. Marty also represents several public companies in a general counsel capacity, as well as investment banks and placement agents in PIPEs and public offerings. Marty has counseled issuers and underwriters in more than 50 offerings.

Recognized in Chambers USA: America's Leading Lawyers for Business since 2011, Marty is “highly respected for the superlative quality of the corporate counsel he offers corporate clients.” Sources describe him as a “a trusted partner” who “consistently delivers great advice” with a “specialty in managing complex and difficult stalemates.”

Education
  • J.D., Georgetown University Law Center, 1991
  • B.A., Georgetown University, 1988Cum Laude
Associations and Memberships
  • Member, Board of Directors, Wilson Sonsini Goodrich & Rosati
  • Former Member, Board of Directors, COMMNEXUS
  • Former Member, Board of Directors, CONNECT
  • Co-founder, PEERs Network
Honors
  • Named among San Diego Business Journal’s 2025 “Leaders of Influence in Life Sciences”
  • Named among Southern California's top corporate attorneys in the 2011-2026 editions of Chambers USA: America's Leading Lawyers for Business, earning kudos for his representation of emerging growth companies and seen as “pragmatic, forward-thinking and thorough"
  • Selected for inclusion in the 2023-2024 editions of Best Lawyers in America
  • Recognized among San Diego's top corporate attorneys for 2011 and 2012 by San Diego Metropolitan Magazine
  • Recognized as a "Life Science Star" in the finance and transactional section of LMG Life Sciences in 2012 and 2013
  • Named to "Lawdragon 500 Leading Dealmakers"
  • Named to "Lawdragon 500 New Stars, New Worlds"
  • Ranked by the IPO Journal in the top 10 of the publication's "Top 100 Lawyers Acting as IPO Issuer's Counsel"
Admissions
  • State Bar of California
  • State Bar of New York
  • State Bar of Wyoming
Credentials
Education
  • J.D., Georgetown University Law Center, 1991
  • B.A., Georgetown University, 1988Cum Laude
Associations and Memberships
  • Member, Board of Directors, Wilson Sonsini Goodrich & Rosati
  • Former Member, Board of Directors, COMMNEXUS
  • Former Member, Board of Directors, CONNECT
  • Co-founder, PEERs Network
Honors
  • Named among San Diego Business Journal’s 2025 “Leaders of Influence in Life Sciences”
  • Named among Southern California's top corporate attorneys in the 2011-2026 editions of Chambers USA: America's Leading Lawyers for Business, earning kudos for his representation of emerging growth companies and seen as “pragmatic, forward-thinking and thorough"
  • Selected for inclusion in the 2023-2024 editions of Best Lawyers in America
  • Recognized among San Diego's top corporate attorneys for 2011 and 2012 by San Diego Metropolitan Magazine
  • Recognized as a "Life Science Star" in the finance and transactional section of LMG Life Sciences in 2012 and 2013
  • Named to "Lawdragon 500 Leading Dealmakers"
  • Named to "Lawdragon 500 New Stars, New Worlds"
  • Ranked by the IPO Journal in the top 10 of the publication's "Top 100 Lawyers Acting as IPO Issuer's Counsel"
Admissions
  • State Bar of California
  • State Bar of New York
  • State Bar of Wyoming

Public Offerings

  • Illumina IPO
  • Immunity Bio (formerly Nantkwest IPO)
  • Inogen IPO
  • RXST IPO
  • Lenz IPO
  • Ventyx IPO

Mergers & Acquisitions and Strategic Partnerships

  • DTX Pharma sale to Novartis
  • Vertos Medical sale to Stryker
  • Technosylva strategic growth investment from TA Associates
  • CoreValve sale to Medtronic
  • Eyeonics sale to Bausch & Lomb

Venture Financings

  • Represented Concentric Analgesics in its $76 million Series B 
  • Represented ABK Biomedical in its $30 million Series B 
  • Represented Vertiflex in its $40 million Series C 
Select Transactions

Public Offerings

  • Illumina IPO
  • Immunity Bio (formerly Nantkwest IPO)
  • Inogen IPO
  • RXST IPO
  • Lenz IPO
  • Ventyx IPO

Mergers & Acquisitions and Strategic Partnerships

  • DTX Pharma sale to Novartis
  • Vertos Medical sale to Stryker
  • Technosylva strategic growth investment from TA Associates
  • CoreValve sale to Medtronic
  • Eyeonics sale to Bausch & Lomb

Venture Financings

  • Represented Concentric Analgesics in its $76 million Series B 
  • Represented ABK Biomedical in its $30 million Series B 
  • Represented Vertiflex in its $40 million Series C 
Focus Areas
  • Biotech
  • Capital Markets
  • Corporate
  • Corporate Governance
  • Corporate Life Sciences
  • Emerging Companies and Venture Capital
  • Life Sciences
  • Mergers & Acquisitions
Recent Insights
News Articles
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Learn More
Client Highlights
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Learn More
View All
Recent Events
Affiliated Programs
BioTools Innovator 2025 Capstone Event
Wilson Sonsini is proud to be an event sponsor for the Biotools Innovator Capstone Event on November 18th. The BioTools Innovator Capstone is the premier showcase for innovation in life science tools and diagnostics, bringing together leading pharma and biotech startups to present their groundbreaking technologies to a panel of judges, including Wilson Sonsini partners, Eric Hsu, Ingo Hardt, Marty Waters, and Bu Yin.
Learn More
Affiliated Programs
Octane’s Ophthalmology Tech Forum 2025
Wilson Sonsini is proud to support Octane’s Ophthalmology Tech Forum 2025, returning June 26-27, at the VEA in Newport Beach.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.